Clavis Pharma - On track for Q4 pancreatic data
Aug 28th 2012 - Edison Investment Research today published a report on Clavis Pharma entitled "On Track For Q4 Pancreatic Data". In summary, the report says:
Interim results show Clavis is on track clinically and financially. The two key trial reporting periods remainQ412 for CP-4126 in pancreatic cancer and Q113 for elacytarabine in refractory and relapsed AML. The pivotal CP-4126 trial might allow a 2013FDA submission by the global partner, Clovis. The small CP-4126 trial in refractory pancreatic cancer has closed. Elacytarabine will be partnered in the US if successful and marketed directly in Europe.The combination AML study has shown a 45% response rate so far and will be reported at a major US conference in December.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
